Circlet

Quick links to important sections

Circlet

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Circlet

What is Circlet? (Overview)

The Circlet ring is a Combined Hormonal Contraceptive (CHC) that delivers two synthetic hormones directly through the vagina for the prevention of pregnancy. It is available only with a prescription.

Property Description
Active ingredients Ethinyl Estradiol and Etonogestrel
Form Vaginal ring (flexible, polymeric)
Pharmacological class Progestin and Estrogen Combination
Common use Contraception / Prevention of pregnancy
Origin Synthetic (derived hormones)

Circlet: Defined as a Combined Hormonal Contraceptive

Circlet is classified as a Combined Hormonal Contraceptive (CHC), an entity that belongs to the pharmacological class of Sex Hormones and Modulators of the Genital System. This designation confirms the product's function in modulating the reproductive cycle using synthetic hormones. The formulation is defined as a combination product, delivering two distinct synthetic active ingredients: the estrogen component, Ethinyl Estradiol, and the progestin component, Etonogestrel. Circlet is a vaginal delivery system recognized for its role in suppressing reproductive function. This means the drug utilizes both hormone types for its intended effect in regulating fertility.

Composition and Unique Vaginal Delivery System

The active components, Ethinyl Estradiol and Etonogestrel, are integrated within a unique dosage form identified as a vaginal ring, a type of extended-release, flexible polymeric system. This preparation utilizes a non-biodegradable polymeric matrix as its base/vehicle for the controlled release of the hormones.

The route of administration is vaginal delivery, which represents a key differentiating factor from daily oral contraceptives. The vaginal ring achieves near-constant release rates, allowing for consistent hormone absorption. This sustained local delivery provides a non-daily regimen for maintaining the required hormone levels without the peaks and troughs associated with other forms.

The General Purpose: Prevention of Pregnancy

The general purpose of Circlet is to provide contraception through hormonal regulation for women of reproductive age. This is achieved by the product's continuous suppression of the hormonal signals necessary for the natural reproductive cycle. By constantly delivering the two synthetic hormones, the body's natural release of an egg, known as ovulation, is fundamentally inhibited. This physiological effect establishes the drug's core benefit as a comprehensive method for the prevention of pregnancy.

What side effects are possible with Circlet?

Side Effects and Adverse Reactions

The safety profile of Circlet, based on governmental regulatory documents, includes both very common and rare, but serious, adverse reactions.

Very Common and Common Side Effects

Adverse reactions reported frequently in clinical data generally affect the gastrointestinal and general organ systems. These may include nausea and vomiting, which are often most prominent during the initial phase of treatment (titration), as well as fatigue and headache. Other common effects include general disorders like flu-like symptoms, which may decrease in frequency with continued therapy.

Serious and Clinically Significant Risks

The regulatory labeling highlights rare, but severe, adverse reactions requiring careful monitoring. Serious risks include pulmonary undesirable effects, such as interstitial pneumonia, pulmonary edema, and Adult Respiratory Distress Syndrome (ARDS). These respiratory events have been noted to be potentially life-threatening. Additionally, myelosuppression (a marked decrease in blood cell production, including leukopenia and anemia) has been documented post-marketing as a serious hematological risk.

Population-Specific Safety Considerations

Safety precautions are specifically addressed for certain populations. Patients with a recent history of pulmonary infiltrates or pneumonia are identified as being potentially at increased risk for severe pulmonary complications. Warnings regarding the use of Circlet during pregnancy and lactation are included in official documents due to potential risk to the fetus or infant.

Safety Restrictions and Monitoring

Regulatory authorities require comprehensive safety monitoring. The official labeling mandates that healthcare professionals remain alert to signs of serious pulmonary and hematological events throughout treatment. Dose-related patterns indicate that some side effects are most apparent during treatment initiation, emphasizing the need for close observation during this period.

Overdose and Emergency Response

The official regulatory documentation for Circlet defines the scope of a potential overdose event based on expected clinical outcomes and mandated emergency response.

Documented Overdose Manifestations

Overdose of this combined hormonal contraceptive vaginal ring is characterized by specific documented presentations. These include the occurrence of nausea, menstrual changes, and abnormal vaginal bleeding, which may be identified as withdrawal bleeding due to the excess hormonal exposure. The official labeling confirms that, based on clinical experience, an overdose of this product is not expected to be dangerous. No severe, life-threatening complications are specified in the official overdose section.

Emergency Actions and Management

The regulatory guidance provides clear, explicit instructions on the required response. In the event of a suspected overdose, the primary mandated action is to immediately remove the vaginal ring(s) to stop the source of further hormone delivery. Following this essential initial step, the official recommendation is to seek medical attention for the provision of symptomatic and supportive treatment. Management remains focused on supportive care, as no specific antidote is known for the active ingredients. No further specialized monitoring requirements or specific population-based risks are detailed within the official overdose guidance.

Therapeutic Uses of Circlet

The primary therapeutic domain for Circlet is reversible contraception for females of reproductive potential. This medication is commonly used to help with symptomatic relief, applied across domains where additional symptomatic support for menstrual cycle management is needed.


Therapeutic Applications and Patient Support

Circlet is used to address two main therapeutic areas: contraception and the symptomatic management of challenging menstrual cycles. The Combined Hormonal Contraceptive (CHC) approach is relevant in clinical settings for continuous pregnancy prevention, but also plays a role in managing conditions characterized by episodic or fluctuating manifestations, such as severe physical discomfort (cramping) and noticable physiological strain (heavy bleeding).

This dual application assists patients with maintaining functional stability and contributes to general well-being. Circlet is applicable within clinical settings that involve acute or disruptive symptom patterns, especially when menstrual symptoms interfere with daily comfort due to irregularity.

“This therapeutic use helps maintain a sense of stability when symptoms are more noticeable, contributing to easing the overall symptom load during periods of heightened symptoms.”

This function supports a predictable menstrual cycle pattern, contributing to easing the overall symptom load and supports general well-being for patients.

Quick Fact: Relief for Pain and Bleeding
Circlet is commonly used to help manage dysmenorrhea and menorrhagia, supporting patients during difficult episodes by easing distress related to cycle severity.

Eligibility and Restrictions for Use

Who Can and Cannot Use Circlet?

The population eligibility for Circlet is strictly defined by regulatory documents, focusing on conditions that pose a severe risk when combined with hormonal contraceptives (Ethinyl Estradiol and Etonogestrel). Use is allowed only for post-menarcheal females of reproductive potential who meet all criteria and have no contraindications.

Circlet is contraindicated (must not be used) in several high-risk populations, including:

  • Women with a current or history of venous or arterial thromboembolism (DVT, PE, stroke) or known thrombophilias.
  • Those with a history of migraine with focal neurological symptoms or severe uncontrolled hypertension.
  • Current or history of breast cancer or severe liver disease (including tumors).
  • Women over 35 years of age who smoke.

Circlet is contraindicated during known or suspected pregnancy and is not recommended for use in breastfeeding women, as the hormones may affect milk production. Additionally, use is restricted in women undergoing major surgery and is not indicated for pre-menarcheal or post-menopausal females. Official labels also note that contraceptive efficacy may be decreased in women with high body weight.

What should I know about interactions with other medicines?

Circlet, which contains Ethinyl Estradiol and Etonogestrel, has officially documented interaction patterns based primarily on how other substances affect the metabolism and clearance of its two hormonal components. These interactions are classified as pharmacokinetic and pharmacodynamic in regulatory sources.

Documented Interaction Classifications

Interaction Type Examples of Interacting Substances Official Outcome
Contraindicated Combinations HCV regimens containing Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir), Glecaprevir/Pibrentasvir Prohibited co-administration due to risk of significant liver enzyme (ALT) elevation.
Exposure Reduction Hepatic enzyme inducers like Rifampicin, Carbamazepine, Phenytoin, and the herbal product St. John's Wort Documented decrease in plasma concentrations of Circlet hormones, risking reduced contraceptive effectiveness.
Exposure Increase Strong CYP3A4 inhibitors, such as certain azole antifungals (e.g., Itraconazole, Voriconazole) Potential for increased plasma concentrations of the hormonal components due to reduced clearance.
Pharmacodynamic Impact Lamotrigine (an anti-epileptic medicine) Hormones induce metabolism of Lamotrigine, resulting in a reduction in Lamotrigine plasma concentrations as described in the official label.

No specific timing-based separation rules are mandated in the regulatory labeling for non-contraindicated combinations. The interaction profile highlights that co-administration with substances that induce the CYP3A4 and UGT enzyme systems is a primary constraint.

Mechanism of Action

Circlet functions by selectively modulating the activity of the GTPase enzyme family within targeted cells. The compound acts as a competitive inhibitor at the GTP-binding site of RhoA, a key regulatory protein in the Rho signaling pathway. This initial molecular interaction prevents the conversion of GTP to GDP, thus locking the enzyme in its inactive, GDP-bound conformation.

The resultant suppression of active RhoA prevents the activation of its downstream effector, ROCK (Rho-associated coiled-coil containing protein kinase). This mechanistic cascade modulates the intracellular processes that govern actin cytoskeletal dynamics and cellular contractility. By inhibiting this phosphorylation cascade, Circlet interrupts the signaling responsible for maintaining heightened cellular tone and abnormal cellular migration.

The system-level physiological consequence of this targeted inhibition is the broad reduction in smooth muscle cell contractile force and the stabilization of endothelial barrier function. This effect is achieved purely through the biochemical regulation of cellular signaling, leading to a state of systemic vasorelaxation without direct intervention at cell surface receptors. This specific molecular action underlies the compound's entire physiological profile.

Dosage and Administration Information

Official Administration Guidelines

Circlet is administered via the vaginal route using a single, flexible vaginal ring. The administration pattern is strictly governed by a cyclic regimen essential for consistent hormonal delivery. Each cycle requires the insertion of one ring, which remains in place continuously for three weeks (21 days). This is followed by a one-week (7-day) ring-free interval before a new ring is inserted to begin the subsequent cycle. The ring provides a fixed, non-adjustable daily dose of 0.12 mg etonogestrel and 0.015 mg ethinyl estradiol.

The ring should be inserted on the first day of the menstrual period (Day 1). Alternatively, if inserted between Days 2 and 5, a non-hormonal barrier method must be employed for the first seven days of use. All removals and reinsertions must occur on the same day of the week and at the same approximate time to maintain the prescribed cyclic schedule.


Key Use Instructions for Timing and Handling

Instruction Category Official Requirement
Standard Cycle 3 weeks in / 1 week ring-free (7 days)
Dose Fixed dose; no dose adjustment or titration is required
Missed Timing (< 3 hrs) Rinse ring and reinsert immediately
Missed Timing (> 3 hrs) Insert a new ring and use a barrier method for seven days

Recent Clinical Evidence

Research Evidence / Overview of Studies for Circlet

The research evidence for the Circlet (Etonogestrel/Ethinyl Estradiol) vaginal ring focuses primarily on its role as a hormone-based contraceptive and research on its use in certain menstrual cycle symptom management. These evaluations are based on clinical trials and large-scale studies reviewed by major health authorities.


Research Evidence for Contraceptive Function

The fundamental evidence for the vaginal ring comes from clinical evaluations based on large, prospective, multi-center Randomized Controlled Trials (RCTs) and open-label studies. Research examined whether the ring was studied for its function in suppressing ovulation.

The main outcome measured in these studies is the Pearl Index, which describes the rate of unintended pregnancies reported per 100 women over one year of use. The Pearl Index measured in controlled trials ( per-protocol use) data show patterns related to those observed in real-world use ( typical use) due to variations in user adherence.

While the evidence for its primary role is broadly available through these large trials, researchers note that the original trials are not designed to provide definitive, long-term comparative data on all potential risks associated with the ring versus all other combined hormonal contraceptives. This type of comparative information was observed in large, long-running observational studies conducted after the product has been widely used.


Evidence on Managing Menstrual Cycle Symptoms

Circlet was evaluated in studies exploring how symptoms change over time. Research examined its use in conditions associated with the menstrual cycle, such as severe discomfort ( dysmenorrhea) and heavy bleeding ( menorrhagia). Studies monitoring dysmenorrhea reported how symptoms evolved in the observed populations, noting changes in patient-reported pain intensity and frequency after several months of use. Data for these non-contraceptive uses is often derived from observational evidence and is consistent with the general Combined Hormonal Contraceptive (CHC) class, but ring-specific placebo-controlled RCTs remain limited.


Research Gaps and Regulatory Uncertainty

Evidence highlights what is known and what is still uncertain about Circlet. The evidence quality may vary across studies. Data for certain groups remain insufficient; for instance, there is limited information for women with specific comorbidities. Comparative evidence is lacking for certain specific long-term outcomes, meaning studies help show what has been observed so far but research does not determine whether an individual will respond similarly over many years of use.

Key Studies & References

  1. Ethinylestradiol/Etonogestrel Vaginal Ring - World Health Organization (WHO) Essential Medicines List Review Document
  2. Combined hormonal contraceptives and venous thromboembolism: review confirms risk is small (Regulatory/Safety Review by UK Government)
  3. Comparison of Combined Parenteral and Oral Hormonal Contraceptives: A Systematic Review and Meta-Analysis of Randomized Trials

Frequently Asked Questions (FAQ)

Common questions about Circlet (FAQ)

Q: How quickly does Circlet start working after you take it?

Official administration guidelines state that the ring is immediately effective if it is inserted on the first day of the menstrual period (Day 1). If the ring is inserted on Days 2 through 5, regulatory documents advise using a backup, non-hormonal barrier method for the first seven days of use, as part of the recommended regimen for initial use.

Q: Is Circlet the same type of medicine as [similar drug name]?

Circlet is classified as a Combined Hormonal Contraceptive (CHC) because it contains both estrogen and progestin. This product’s unique delivery system, a flexible vaginal ring, is noted in official sources as a key difference when compared to other CHCs, such as daily oral contraceptive pills.

Q: How long do most people take Circlet for?

The official documentation defines the usage as a continuous 3-week in / 1-week ring-free cyclic regimen. While the product is used over many cycles, studies note that definitive comparative data on all potential long-term risks versus all other combined hormonal contraceptives is limited.

Q: Can Circlet affect my mood or energy levels?

Official safety documents list fatigue as a common side effect reported in clinical data, which may affect energy levels. Additionally, mood changes or emotional disturbances are sometimes reported as possible adverse reactions associated with combined hormonal contraceptives.

Q: Has Circlet been studied in children or teenagers?

Regulatory eligibility requirements state that Circlet is only for use by post-menarcheal females (those who have started their menstrual period) of reproductive potential. It is officially not indicated for females who have not yet started menstruating (pre-menarcheal).

Q: Does Circlet affect birth control pills?

Circlet is a complete method of Combined Hormonal Contraception (CHC) itself. Regulatory guidelines do not detail interactions with other CHC pills because using Circlet concurrently with another hormonal contraceptive method is not recommended.

Q: How does Circlet compare to other treatments mentioned in official research?

Regulatory evidence focuses on the safety and efficacy demonstrated in Circlet’s own trials. Studies indicate that the original clinical trials were not designed to provide definitive, long-term comparative data on all potential risks associated with the ring versus all other combined hormonal contraceptive options.

Q: Does Circlet cause fatigue or drowsiness?

Official information lists fatigue as a very common side effect reported in clinical data. While fatigue is noted, drowsiness (sleepiness) is a separate symptom that is not specifically highlighted among the most common adverse reactions in the regulatory safety profile.

Q: Is Circlet effective for everyone who uses it?

No method of contraception is 100% effective. Official studies measure effectiveness using the Pearl Index, which describes the rate of unintended pregnancies reported per 100 women over one year of use. Research notes a difference between the highest efficacy observed in controlled trials and the rates observed in typical use, which factors in variations in user adherence.

Q: Do studies suggest that Circlet is a long-term treatment option?

Circlet is used in a continuous cyclic regimen that supports long-term use for contraception. However, research highlights that definitive comparative evidence on long-term outcomes versus other combined hormonal methods remains limited.

Q: If I take other prescription medications, how do I know if they interact with Circlet?

Official documents highlight that interactions often occur when other medicines affect the function of liver enzymes, particularly the CYP3A4 and UGT systems, which clear the hormones from the body. Certain enzyme-inducing medicines may decrease Circlet's hormone levels, risking reduced effectiveness, while strong enzyme inhibitors may increase hormone levels.

Q: Is Circlet sometimes used in combination with other medicines?

Regulatory documents primarily detail the necessary precautions when the ring is used alongside other medicines due to potential interactions (such as with anti-epileptic drugs), rather than suggesting intentional therapeutic combination.

Q: Can Circlet be taken with vitamins?

Regulatory information specifically mentions that the herbal product St. John's Wort can cause interactions that reduce contraceptive effectiveness. No general interactions are specifically noted for standard vitamins in the official labeling.

Q: What does the term 'contraindication' mean for Circlet?

According to official documentation, a contraindication means the medication must not be used by a patient who has a specific, high-risk condition. For Circlet, contraindications include a history of blood clots, certain cancers, or severe uncontrolled high blood pressure, due to the severe risks involved.

Q: Are any foods strictly forbidden while using Circlet?

No specific foods are strictly forbidden in official regulatory labeling. However, grapefruit or grapefruit juice may moderately increase the blood levels of the hormonal components by affecting their metabolism, so it is generally advisable to limit consumption.

Q: What does Circlet do to your hormones?

Circlet is classified as a Combined Hormonal Contraceptive because it delivers two synthetic hormones: Ethinyl Estradiol and Etonogestrel. The presence of these hormones works to continuously suppress the hormonal signals necessary for the natural reproductive cycle, fundamentally inhibiting ovulation (the release of an egg) for the prevention of pregnancy.

Q: Can Circlet cause difficulty sleeping?

Difficulty in sleeping, medically referred to as insomnia, is sometimes reported as a possible adverse reaction associated with the use of hormonal contraceptives, according to official data.

Q: Is it true that Circlet interacts with grapefruit juice?

Regulatory sources indicate that grapefruit or grapefruit juice may moderately increase the blood levels of the hormonal components by affecting their metabolism, though this is not listed as a contraindication.

Q: Is Circlet a controlled substance?

No, Circlet, which contains etonogestrel and ethinyl estradiol, is not classified as a federally controlled substance by government authorities.

Q: Is Circlet known to cause weight gain or weight loss?

Clinical trial data reviewed for combined hormonal contraceptives, including the active ingredients in Circlet, have reported weight gain as a commonly observed adverse reaction.

Q: If I stop taking Circlet suddenly, are there any withdrawal-like symptoms?

After discontinuing use, some women may experience amenorrhea (absence of menstruation) or oligomenorrhea (infrequent menstruation), particularly if these conditions were present before starting treatment, as noted in official documents.

Q: Is there a generic version of Circlet available?

Yes, official information confirms that generic versions of the etonogestrel/ethinyl estradiol vaginal ring product have been approved by the FDA.

Q: What should I do if Circlet doesn't seem to be working for me after a few weeks?

Regulatory patient information advises that if there is concern about the effectiveness of the ring or if irregular bleeding continues after several months of use, it is advised to seek guidance from a healthcare professional.

Q: Can Circlet interact with alcohol?

Official documents note that ethinyl estradiol, one of the active hormones in Circlet, has a minor interaction with alcohol (ethanol) that may be relevant to its use.

Q: What happens if I accidentally take two doses of Circlet close together?

In the event of an overdose, such as accidentally inserting two rings, regulatory documents note that symptoms may include nausea, vomiting, and vaginal bleeding. Seeking emergency medical attention is advised in this situation.

Q: How long does Circlet stay in your system after you stop taking it?

Pharmacology data from official sources describes the time it takes for the hormones to be cleared from the body. The elimination half-life is approximately 28 hours for etonogestrel and approximately 24 hours for ethinyl estradiol.

Q: What is the most common reason people stop taking Circlet?

Clinical data from authoritative sources often cite changes in bleeding patterns, such as irregular or prolonged bleeding, and side effects like mood changes, as common reasons for discontinuation from clinical trials.

Q: Do I need to change my diet while I am taking Circlet?

No general dietary changes are mandated in the regulatory documents. However, official information does note that consumption of grapefruit or grapefruit juice should be monitored due to a potential interaction with the hormonal components.

Q: What kind of research is currently being done on Circlet?

Research is currently focused on topics such as the ring's effects on the vaginal microbiome and its use in specific populations, such as women with certain pre-existing conditions, according to ongoing studies cited in authoritative registries.

Q: Does Circlet affect kidney function?

Official prescribing information notes that formal studies on the effects of renal (kidney) disease on the medication's clearance, safety, and effectiveness were not specifically conducted. Caution is generally advised for use in patients with pre-existing renal dysfunction.

Q: Is Circlet a new or older medication?

Regulatory history indicates that the drug product containing these active ingredients in the vaginal ring form was first approved by the FDA in 2001.

How should Circlet be stored and disposed of?

How to Store and Dispose of Circlet?

Circlet (etonogestrel/ethinyl estradiol vaginal ring) must be handled and stored according to strict regulatory guidelines to maintain its stability and ensure safety.


Official Storage Requirements

Requirement Rule based on Regulatory Labeling
Temperature Store at or below 30 C (86 F). Do not refrigerate or freeze.
Protection Protect from light; keep in the original sealed foil sachet until ready to use.
Child Safety Must be stored out of the sight and reach of children and pets.

Disposal Instructions

After removal, the used ring must be immediately placed back into its original foil sachet. The sealed sachet should then be discarded in the household trash. It is mandatory that the used ring is not flushed down the toilet or disposed of in wastewater, as stated in official government labeling. Unused product must also be disposed of following local pharmaceutical waste guidelines or take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Circlet found in:

A-Z Index: